Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment
Seung Kak Shin1, Young Kul Jung, Hyun Hwa Yoon
1Department of Internal Medicine, Gachon University Gil Medical Center, 21 Namdong-daero 774 beon-gil, Namdong-gu, Incheon 405-760, Korea.
Abstract:
Hepatocellular carcinoma (HCC) is a critical global health issue and the third most common cause of cancer-related deaths worldwide. The majority of patients who present HCC are already at an advanced stage and their tumors are unresectable. Sorafenib is a multi-kinase inhibitor of the vascular endothelial growth factor pathway and was recently introduced as a therapy for advanced HCC. Furthermore, studies have shown that oral sorafenib has beneficial effects on survival. However, many patients experience diverse side effects, and some of these are severe. Liver abscess development has not been previously documented to be associated with sorafenib administration in HCC. Here, we report the case of a HCC patient that developed a liver abscess while being treated with sorafenib.
Insights
Hepatocellular carcinoma (HCC) patients treated with sorafenib may develop liver abscesses. This case report highlights a previously undocumented adverse event associated with this advanced cancer therapy.
Area of Science:
- Oncology
- Hepatology
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally, often diagnosed at unresectable stages.
- Sorafenib, a multi-kinase inhibitor, is a standard therapy for advanced HCC, improving patient survival.
- While sorafenib offers survival benefits, it is associated with various adverse effects.
Observation:
- A patient with advanced hepatocellular carcinoma (HCC) was undergoing treatment with sorafenib.
- During sorafenib therapy, the patient developed a liver abscess.
- This adverse event, liver abscess formation, has not been previously reported in association with sorafenib use in HCC.
Findings:
- This case presents the first documented instance of liver abscess development in a patient with HCC receiving sorafenib treatment.
- The occurrence suggests a potential, previously unrecognized association between sorafenib and liver abscess formation.
Implications:
- Clinicians should be aware of liver abscess as a potential, albeit rare, complication in HCC patients treated with sorafenib.
- Further investigation may be warranted to elucidate the mechanism linking sorafenib to liver abscess development.
- This finding could influence monitoring strategies and patient management in advanced HCC therapy.
